Vimelea Therapeutics, Inc.

Vimelea Therapeutics, Inc.Vimelea Therapeutics, Inc.Vimelea Therapeutics, Inc.

Vimelea Therapeutics, Inc.

Vimelea Therapeutics, Inc.Vimelea Therapeutics, Inc.Vimelea Therapeutics, Inc.

About Us

What We Do

  

Vimelea Therapeutics is a pre-clinical stage drug development company. We are developing a novel platform of therapeutic small molecules that treat various inflammatory diseases. Our new class of chemical compounds were designed from an immunomodulating system in nature. Our library of small molecules provides numerous development opportunities for our therapeutic target, cutaneous lupus erythematosus (CLE), as well as a significant number of other autoimmune and chronic inflammatory disease.

Competitive Advantage

  

Vimelea’s lead compounds modulate both myeloid and lymphoid immune cells. Both cell types play a role in CLE pathology. Our compounds are only active in unbalanced immune tissue, thus mitigating toxicity in healthy tissue. The compounds’ size and chemical structures also make for efficient manufacturing.

Team

  

Founder

Dr. Darius M. Walker 


Business Advisors

Dr. Aubrey Watkins III

Mr. Steven M. Walker, MBA, MHA

Dr. Christine Copple

Mr. Brad Stewart

Mr. Jarrod Longcor, MBA, MPH, MSMS




Scientific Advisors

Prof. William Harnett

Prof. Colin Suckling


Contact Us

Vimelea Therapeutics, Inc.

9711 Washingtonian Boulevard, Suite 550 Gaithersburg, Maryland 20878, United States

info@vimelea-thera.com 1-717-547-4537

Send Message

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cancel

Copyright © 2023 Vimelea Therapeutics, Inc. - All Rights Reserved.


Powered by GoDaddy

This website uses cookies.

We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.

Accept